

AMENDMENTS TO THE CLAIMS

1. **(Currently amended)** An immunogenic composition comprising:

- (a) a first ~~an~~ agent capable of raising an immune response against *Mycoplasma cynos* (*M. cynos*) in a dog, ~~and wherein said agent comprises inactivated or attenuated *M. cynos*, and further comprising~~
- (b) a second ~~an~~ agent ~~comprising one or more agents~~ selected from the group consisting of:
- (i) an agent capable of raising an immune response against *Streptococcus equi sub species zooepidemicus* (*S. zooepidemicus*) in a dog, ~~wherein the agent capable of raising an immune response against *S. zooepidemicus* in a dog comprises inactivated or attenuated *S. zooepidemicus*, and~~
 - (ii) an agent capable of raising an immune response against a *Chlamydophila* in a dog;

wherein said first agent comprises inactivated or attenuated *M. cynos* and said second agent comprises: (i) inactivated or attenuated *S. zooepidemicus*, or (ii) inactivated or attenuated
~~wherein the agent capable of raising an immune response in a dog against a *Chlamydophila* comprises inactivated or attenuated *Chlamydophila abortus*, *Chlamydophila felis*, *Chlamydia muridarum*, *Chlamydia pecorum*, *Chlamydia pneumoniae*, *Chlamydia suis* or *Chlamydia trachomatis*.~~

2.-7. **(Canceled)**

8. **(Previously presented)** A pharmaceutical composition comprising an immunogenic composition according to Claim 1 and a pharmaceutically acceptable carrier, diluent or adjuvant.

9. **(Previously presented)** The immunogenic composition according to Claim 1 further comprising any one or more of:

an agent capable of raising an immune response in a dog against canine respiratory coronavirus (CRCV), wherein said CRVC is a Group II coronavirus;

an agent capable of raising an immune response in a dog against canine parainfluenzavirus (CPIV);

an agent capable of raising an immune response in a dog against canine adenovirus type 2 (CAV-2);

an agent capable of raising an immune response in a dog against canine herpesvirus (CHV); and

an agent capable of raising an immune response in a dog against *Bordetella bronchiseptica* (*B. bronchiseptica*).

10. **(Previously presented)** An immunogenic composition according to Claim 9 wherein the agent capable of raising an immune response in a dog against CRCV comprises inactivated or attenuated CRCV.

11. **(Previously presented)** An immunogenic composition according to Claim 9 wherein the agent capable of raising an immune response in a dog against CRCV comprises a Spike protein or a hemagglutinin-esterase (HE) protein of CRCV, or an immunogenic portion of the Spike or HE protein.

12. **(Previously presented)** An immunogenic composition according to Claim 9 wherein the agent capable of raising an immune response in a dog against CPIV comprises inactivated or attenuated CPIV.

13. **(Previously presented)** An immunogenic composition according to Claim 9 wherein the agent capable of raising an immune response in a dog against CAV-2 comprises inactivated or attenuated CAV-2.

14. **(Previously presented)** An immunogenic composition according to Claim 9 wherein the agent capable of raising an immune response in a dog against CHV comprises inactivated or attenuated CHV.

15. **(Previously presented)** An immunogenic composition according to Claim 9 wherein the agent capable of raising an immune response in a dog against *B. bronchiseptica* comprises inactivated or attenuated *B. bronchiseptica*.

16. **(Withdrawn)** A method of eliciting an immune response in a dog comprising administering to the dog an immunogenic composition according to Claim 1.

17. **(Withdrawn)** A method of treating CIRD in a dog comprising administering to the dog an immunogenic composition according to Claim 1.

18. **(Withdrawn)** A method of stimulating an immune response against *M. cynos* and an organism selected from *S. zooepidemicus* and a *Chlamydomphila*, the method comprising administering to a dog an immunogenic composition according to Claim 1, wherein said

immunogenic composition stimulates an immune response against *M. cynos* and an organism selected from *S. zooepidemicus* and a *Chlamydomphila* in the dog.

19. **(Withdrawn)** The method according to Claim 18 further comprising administering to the dog any one or more of:

an agent capable of raising an immune response in a dog against CRVC,
wherein said CRVC is a Group II coronavirus;

an agent capable of raising an immune response in a dog against CPIV;

an agent capable of raising an immune response in a dog against CAV-2;

an agent capable of raising an immune response in a dog against CHV; and

an agent capable of raising an immune response in a dog against *B.*

bronchiseptica.

20.-63. **(Canceled)**

64. **(New)** An immunogenic composition comprising:

- (a) a first agent capable of raising an immune response against *Mycoplasma cynos* (*M. cynos*) in a dog, wherein said first agent comprises inactivated or attenuated *M. cynos*;
- (b) a second agent capable of raising an immune response against *Streptococcus equi sub species zooepidemicus* (*S. zooepidemicus*) in a dog, wherein said first agent comprises inactivated or attenuated *S. zooepidemicus*; and
- (c) a third agent capable of raising an immune response against a *Chlamydomphila* in a dog, wherein said first agent comprises inactivated or attenuated *Chlamydomphila abortus*, *Chlamydomphila felis*, *Chlamydia muridarum*, *Chlamydia pecorum*, *Chlamydia pneumoniae*, *Chlamydia suis* or *Chlamydia trachomatis*.